Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

INTRODUCTION: BAY 81‐8973 (Kovaltry(®)) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on‐demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Renchi, Sun, Jing, Zhao, Yongqiang, Wang, Xuefeng, Wu, Depei, Tseneklidou‐Stoeter, Despina, Wu, Junde, Church, Nikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850381/
https://www.ncbi.nlm.nih.gov/pubmed/30993836
http://dx.doi.org/10.1111/hae.13751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850381/
https://www.ncbi.nlm.nih.gov/pubmed/30993836
http://dx.doi.org/10.1111/hae.13751

Ejemplares similares